Intellectual property (IP) strategy in the life sciences evolves as rapidly as the scientific breakthroughs driving the industry. Since the America Invents Act reshaped the U.S. patent system more than a decade ago, courts and policymakers have continued to refine how its provisions apply, particularly in areas critical to life sciences, such as patent subject matter eligibility, biosimilar development, and regulatory exclusivities. Protecting innovation in this environment requires more than strong patents. Life sciences companies must also safeguard trade secrets, secure trademarks that reinforce brand identity, and anticipate how competitors may challenge or design around their IP.
Please see full publication below for more information.
